Key points are not available for this paper at this time.
People with a mutation in a proteolytic enzyme are at a substantially lower risk for coronary heart disease because of their lifelong reduction of plasma low-density lipoprotein.
Brown et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: